Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit

• DOI: 10.1111/cas.16061
• Publication Date: 2024-01-23T04:53:48Z
• Authors: Masahiro Hosonuma; Yuya Hirasawa; Atsuo Kuramasu; Masakazu Murayama; Yoichiro Narikawa; Hitoshi Toyoda; Yuta Baba; Junya Isobe; Eiji Funayama; Kohei Tajima; Midori Shida; Kazuyuki Hamada; Toshiaki Tsurui; Hirotsugu Ariizumi; Tomoyuki Ishiguro; Risako Suzuki; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Takehiko Sambe; Mayumi Tsuji; Satoshi Wada; Yuji Kiuchi; Shinichi Kobayashi; Takuya Tsunoda; Kiyoshi Yoshimura
• Keywords: Immune checkpoint

Abstract Immune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%–30%; consequently, prognostic and immune‐related adverse event (irAE) predictors are being explored. The programmed cell death protein 1 (PD‐1) receptor occupancy (RO) PD‐1 inhibitors depends on number peripheral blood lymphocytes their expression levels, suggesting that RO may be related to efficacy events. As inhibition affects each T‐cell subset differently, population must characterized. relevant data have not been reported, relevance this parameter is known. In study, we aimed clarify association between nivolumab patient prognosis reveal development irAEs nivolumab‐treated patients. Thirty‐two patients were included mean follow‐up period was 364 days. effector regulatory T cells (eTregs) significantly lower group presented clinical benefits, significant negative observed eTregs all‐cause mortality. results suggest factor therapy, implying PD‐1/PD‐ligand (PD‐L1) signaling attenuate antitumor effects.